

DR. DANIEL VITT



Dr. Daniel Vitt is CEO of Immunic AG, a German biotech company targeting chronic inflammatory and autoimmune diseases with innovative small molecule therapeutics. He joined Immunic from 4SC AG, a publicly listed stock company based in Martinsried, Germany which he co-founded in 1997. At 4SC he served as CSO and CDO. In this position he transformed 4SC from a research company into an advanced therapeutic development company and brought the company public on German stock exchange in Frankfurt in 2005.

As a member of the executive Board he was responsible for all research and development activities at 4SC group including four clinical stage products. In this position, he essentially contributed to 4SC's maturing therapeutic pipeline and succeeded in bringing several projects in the field of autoimmune diseases, oncology and infectious diseases towards development stage.

Among them 4SCs' phase II products Resminostat, 4SC-202 and IMU-838.

Daniel Vitt studied chemistry in Siegen and Würzburg, Germany from 1989 – 1994 and graduated at the University of Würzburg in the group of G. Bringmann in quantumchemical calculations of organic reactions. During his Ph.D. studies he focused on molecular design of small molecule therapeutics. In 1998 he received his Ph.D. from the Institute of organic chemistry at the University of Würzburg.

Daniel Vitt is managing director of 4SC Discovery GmbH and member of the supervisory board of Quattro Research GmbH. He is member of the Scientific Advisory board of CI3 Cluster in Mainz.

SHORT BIO

SKILLS

Entrepreneurial track record and leadership

EXPERIENCE

Transformation of R&D company to advanced clinical development stage and IPO on German stock exchange

QUALIFICATION

Co-Founder of 4SC AG, managing director and board member of several companies in the life-science industry

MOTIVATION

Leading companies to outstanding levels of excellence